133 related articles for article (PubMed ID: 11033496)
1. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
Detry-Morel M; Dutrieux C
J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
[TBL] [Abstract][Full Text] [Related]
2. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
thoe Schwartzenberg GW; Buys YM
Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
[TBL] [Abstract][Full Text] [Related]
5. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
Lee DA; Gornbein J; Abrams C
J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
[TBL] [Abstract][Full Text] [Related]
7. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
Shi JM; Jiang YQ
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
[TBL] [Abstract][Full Text] [Related]
10. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
11. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
12. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
13. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
Titouamane S; Baudouin C
J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
[TBL] [Abstract][Full Text] [Related]
14. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
[TBL] [Abstract][Full Text] [Related]
15. Side-effect profile of brimonidine tartrate in children.
Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
17. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
18. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
19. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
Motolko MA
Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444
[TBL] [Abstract][Full Text] [Related]
20. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
